Importance Cognitive dysfunction (CD) is recognized by the American Cancer Society as a
treatment effect in head and neck cancer, but the extent of this problem at baseline in
oropharyngeal cancer (OPC), the most common subsite in current practice, to our
knowledge has never been studied. Objective To assess the baseline cognition of patients
with OPC using National Institutes of Health (NIH)-sponsored instruments of Patient-
Reported Outcomes Measurement Information System (PROMIS) and NIH Toolbox …